ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1334

Exploring Canadian Patient Experiences of Living with Lupus Nephritis (LN)

Francesca S Cardwell1, Sydney George2, Adrian Boucher2, Megan R W Barber3, Kim Cheema4, Susan J Elliott5 and Ann E Clarke3, 1University of Waterloo, Department of Geography & Environmental Management, Burlington, ON, Canada, 2GlaxoSmithKline, Health Outcomes and Economics, Mississauga, ON, Canada, 3University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 4University of Calgary, Division of Nephrology, Cumming School of Medicine, Calgary, AB, Canada, 5University of Waterloo, Department of Geography & Environmental Management, Waterloo, ON, Canada

Meeting: ACR Convergence 2022

Keywords: Lupus nephritis, psychosocial factors, Qualitative Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Patient Outcomes, Preferences, and Attitudes Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: LN is one of the most severe manifestations of SLE; however, the patient experience remains understudied. This research investigates patient experiences and perspectives of 1) LN diagnosis; 2) living with LN; and 3) LN healthcare and treatment.

Methods: Patients aged ≥18 years with biopsy-proven pure or mixed ISN/RPS Class III, IV, or V LN and fulfilling the ACR 1997 or SLICC 2012 Classification Criteria for SLE were purposefully recruited from a Canadian lupus cohort to participate in semi-structured in-depth interviews. These were conducted virtually and transcribed verbatim for subsequent thematic analysis using NVivo Qualitative Data Analysis Software.

Results: Nineteen patients with LN were interviewed; 89.5% were female, mean (SD) age was 43.0 (15.7) years, mean (SD) age at SLE diagnosis was 29.8 (13.2) years (Table). Patients reported challenges seeking, receiving, and adjusting to the LN diagnosis, and all described emotional impacts associated with diagnosis (‘The future is really uncertain for me… it’s like a monster hiding around every corner’). Most patients had not heard of LN prior to diagnosis, and this lack of understanding made it difficult to contextualize their illness (Figure).

Patients reported both emotional wellbeing and physical health impacts associated with living with LN. While most have continued in paid employment, patients identified altered career aspirations, role changes, and the need for accommodations in the workplace. Patients also described modified leisure and social activities (‘I stay home instead of being the kill joy… It’s frustrating for me’). While many identified supportive friends and family, a lack of nuanced understanding of their experiences by others was reported (‘I have a sister who has a humongous amount of energy and she thinks I’m just being lazy’). Amongst those of childbearing age before/when diagnosed, LN was described as a factor in their family planning considerations. Specifically, fear of changing LN medications and their reproductive side effects, fear of experiencing a flare while pregnant/when parenting, and concerns about passing on LN/other autoimmune conditions to their children emerged (Figure).

Numerous aspects of LN management present challenges for patients including visiting a range of healthcare providers, taking medication, monitoring diet, stress management, and ensuring adequate rest. While many reported successful LN management with medication, others expressed concern with cost and side effects (‘It’s like doing a dance… sometimes I take two steps back’). The challenges associated with a lack of LN-specific information and resources were identified (Figure).

Conclusion: A lack of individual and public understanding of LN coupled with the uncertainties of diagnosis/living with LN create a substantial psychosocial burden as patients negotiate acceptable risk in the face of uncertainty (eg., in family planning, treatment, paid employment, leisure). Results emphasize the need for wider LN awareness and will inform the development of LN-specific patient resources to increase understanding of LN and better support decision-making.

Funding: GSK (GSK Study 218747)

Supporting image 1

Table. Patient characteristics

Supporting image 2

Figure. Thematic overview


Disclosures: F. Cardwell, None; S. George, GlaxoSmithKline (GSK); A. Boucher, GlaxoSmithKline (GSK); M. Barber, AstraZeneca, GlaxoSmithKline (GSK), Janssen, Sanofi-Genzyme, AbbVie; K. Cheema, Novartis, Alexion; S. Elliott, None; A. Clarke, AstraZeneca, Bristol Myers Squibb (BMS), GlaxoSmithKline (GSK).

To cite this abstract in AMA style:

Cardwell F, George S, Boucher A, Barber M, Cheema K, Elliott S, Clarke A. Exploring Canadian Patient Experiences of Living with Lupus Nephritis (LN) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/exploring-canadian-patient-experiences-of-living-with-lupus-nephritis-ln/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploring-canadian-patient-experiences-of-living-with-lupus-nephritis-ln/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology